The Klein Law Firm announces the commencement of an investigation of Akorn, Inc. (NASDAQ: AKRX) concerning possible violations of federal securities laws.

On February 26, 2018, Fresenius SE & Co. KGaA—which had been expected to close on an acquisition of Akorn—announced that it is conducting an investigation into alleged breaches of U.S. Food and Drug Administration "data integrity requirements relating to product development at Akorn." Following this news, shares of Akorn were down more than 33% on intraday trading on February 27, 2018.

If you suffered a loss in Akorn and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on

Copyright Business Wire 2010